Leukemic patients present significantly higher proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6), at the onset of disease and before cancer therapies, confirming the presence of an inflammatory status in these patients [5]. Here, IL6 is linked to cancer.